• Lipo3K Transfection Reagent for Nucleic Acid Assays

  2026-08-13

  Lipo3K Transfection Reagent combines efficient nucleic acid delivery with a low-toxicity workflow suited to difficult cell models, plasmid expression, siRNA silencing, and co-transfection. This practical guide connects reagent selection and optimization with a 2026 study of pH-responsive antisense oligonucleotide prodrugs in MYCN-amplified cells.

• From P2RX1 Mechanism to Better Apoptosis Assays

  2026-08-12

  A translational perspective on how P2RX1-driven calcium and mitochondrial stress in Ph+ ALL can guide more informative apoptosis and necrosis measurements with the Annexin V-Cy5/DAPI Apoptosis Kit.

• A-1331852: BCL-XL Inhibitor Workflow Guide

  2026-08-12

  A-1331852 is a potent, selective BCL-XL inhibitor for dissecting mitochondrial apoptosis, resistance, and apoptotic priming. This practical guide connects concentration planning, mechanistic readouts, glioblastoma applications, combination sequencing, and troubleshooting.

• MK-2206 and Wnt-Driven Bone Metabolism

  2026-08-11

  Explore how MK-2206 dihydrochloride can help separate Akt phosphorylation from Wnt-driven glycolysis and osteoblast differentiation. This mechanistic perspective connects selective Akt inhibition with assay design, metabolic interpretation, and cancer apoptosis research.

• DNase I (RNase-free) for Cancer RNA Workflows

  2026-08-11

  Learn how to use DNase I (RNase-free) to improve RNA extraction, RT-qPCR, in vitro transcription, and chromatin workflows without compromising RNA integrity. The workflow also translates findings on CAF-derived lactate and oxaliplatin resistance into practical nucleic-acid quality controls.

• Thiothixene Drives Continual Macrophage Efferocytosis

  2026-08-10

  A 2025 Science Signaling study identifies Thiothixene as a repurposing candidate that enhances macrophage clearance of apoptotic and lipid-laden cells, including repeated rounds of efferocytosis. The work connects this activity to Stra6L-dependent vitamin A signaling and Arginase 1 induction while showing that dopamine suppresses efferocytosis and is only partly counteracted by the drug.

• Ziprasidone Augmentation in Anxious Depression

  2026-08-09

  This post-hoc moderator analysis examined whether baseline anxious depression changed the response to ziprasidone added to escitalopram in patients with major depressive disorder. Ziprasidone augmentation showed comparable antidepressant effects across anxiety subgroups, while the apparent anxiety benefit was not clinically meaningful in patients with anxious depression.

• Hepatic sEH–Nrf2 Axis in Osteoporosis

  2026-08-08

  A recent study identifies a liver–bone axis in which hepatic soluble epoxide hydrolase alters circulating epoxyeicosatrienoic acid metabolites, suppresses Nrf2-ARE signaling, and promotes osteoclast differentiation. Its combination of clinical samples, an ovariectomy mouse model, liver-specific manipulation, metabolite analysis, and transcriptomics provides a mechanistic framework for studying redox imbalance in osteoporosis.

• Minoxidil sulphate for Reliable Cell Assays

  2026-08-07

  A scenario-based guide to using Minoxidil sulphate (SKU C6513) in cell viability, proliferation, cytotoxicity, vascular biology, and hair follicle workflows. It connects material quality, solvent handling, potassium-channel biology, and assay interpretation to practical laboratory decisions.

• Machine Learning Advances Lipid Nanoparticle Design for mRNA

  2026-08-07

  This study pioneers a machine learning approach to predict and optimize lipid nanoparticle (LNP) formulations for mRNA vaccine delivery. The integration of a LightGBM algorithm with molecular modeling enables rapid identification of effective ionizable lipid substructures, improving efficiency and reducing experimental burden.

• NU6300 Inhibits Gasdermin D via Cysteine-191 Covalent Modifi

  2026-08-06

  Jiang et al. identify NU6300 as a covalent gasdermin D (GSDMD) inhibitor, targeting cysteine-191 to block both cleavage and palmitoylation events central to pyroptosis. This work clarifies feedback mechanisms in inflammasome signaling and provides a methodological foundation for developing new GSDMD-targeted therapies in inflammatory disease models.

• Vemurafenib (PLX4032): Advancing Melanoma Resistance Researc

  2026-08-06

  This thought-leadership article explores how Vemurafenib (PLX4032) empowers translational research into melanoma cell proliferation inhibition and resistance network mapping. Integrating recent multi-omics insights—especially those revealing ARID1A-dependent resistance mechanisms—this piece bridges deep mechanistic understanding with actionable, strategy-driven guidance. By dissecting the MAPK/ERK pathway, evaluating resistance adaptation, and contextualizing APExBIO’s Vemurafenib within the evolving landscape of cancer biology, we deliver a forward-looking roadmap for researchers seeking to outpace therapeutic resistance in metastatic melanoma.

• E-64 L-trans-epoxysuccinyl Peptide: Precision in Cysteine Pr

  2026-08-05

  E-64, a potent L-trans-epoxysuccinyl peptide, enables irreversible and highly selective cysteine protease inhibition—crucial for dissecting proteolytic pathways in mechanistic and translational research. This article details actionable workflows, troubleshooting strategies, and novel applications, empowering researchers to harness E-64 for reproducible, high-impact experiments.

• 0.4% Trypan Blue Solution: Technical Guide for Cell Viabilit

  2026-08-05

  0.4% Trypan Blue Solution provides a robust method for distinguishing viable from non-viable cells during cell viability measurement, cell counting, and cytotoxicity assays. Its exclusion-based staining enables fast, direct assessment of culture health in research workflows, but it is not intended for diagnostic or clinical use.

• ZK53: Targeted ClpP Activation for Translational Oncology

  2026-08-04

  Explore how ZK53, a selective human mitochondrial serine protease ClpP activator, is redefining mitochondrial dysfunction modeling and anti-cancer strategy in translational research. By integrating recent mechanistic insights and protocol guidance, this article offers strategic direction for researchers navigating the evolving landscape of mitochondrial-targeted oncology.

8071 records 5/539 page Previous Next 12345 下5页 Last page